Edgestream Partners L.P. Takes $1.31 Million Position in Immunome, Inc. $IMNM

Edgestream Partners L.P. acquired a new stake in Immunome, Inc. (NASDAQ:IMNM) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 59,888 shares of the company’s stock, valued at approximately $1,310,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. increased its position in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the period. Primecap Management Co. CA lifted its holdings in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Immunome during the fourth quarter worth $30,710,000. Finally, Sofinnova Investments Inc. grew its stake in shares of Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after purchasing an additional 1,182,426 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Analyst Ratings Changes

IMNM has been the subject of several analyst reports. Citigroup reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Barclays started coverage on Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Immunome presently has a consensus rating of “Moderate Buy” and an average target price of $33.17.

Insiders Place Their Bets

In other Immunome news, CFO Max Rosett sold 60,000 shares of Immunome stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the completion of the sale, the chief financial officer directly owned 54,037 shares in the company, valued at approximately $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the completion of the transaction, the insider directly owned 15,805 shares in the company, valued at approximately $357,509.10. This trade represents a 77.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 472,142 shares of company stock valued at $10,262,648 in the last 90 days. Company insiders own 7.21% of the company’s stock.

Immunome Trading Up 1.1%

Shares of Immunome stock opened at $23.01 on Tuesday. The business has a 50-day moving average price of $21.23 and a two-hundred day moving average price of $22.07. Immunome, Inc. has a 1-year low of $8.66 and a 1-year high of $27.65. The company has a market cap of $2.61 billion, a P/E ratio of -9.67 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Equities research analysts forecast that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.